Chloe James

Summary

Country: France

Publications

  1. ncbi A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
    Chloe James
    INSERM U362, Institut Gustave Roussy, Paris XI University, PR1, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Nature 434:1144-8. 2005
  2. doi The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?
    Chloe James
    Inserm U876, Universite Bordeaux 2, Bordeaux, France
    Hematology Am Soc Hematol Educ Program . 2008
  3. ncbi A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects
    Chloe James
    INSERM U362, Institut Gustave Roussy, Paris XI University, PR1, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Trends Mol Med 11:546-54. 2005
  4. doi The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity
    Chloe James
    INSERM, U876, Bordeaux, France
    Blood 112:2429-38. 2008
  5. doi Mutation in TET2 in myeloid cancers
    Francois Delhommeau
    INSERM U790, Institut Gustave Roussy, Villejuif, France
    N Engl J Med 360:2289-301. 2009
  6. ncbi The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera
    Sabrina Dupont
    INSERM Unité 790, Universite Paris Sud, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Blood 110:1013-21. 2007
  7. ncbi Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells
    Loic Garcon
    Unité U 790 Institut National de la Santé et de la Recherche Médicale INSERM, Institut Gustave Roussy, Villejuif, France
    Blood 108:1551-4. 2006
  8. ncbi Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis
    Ronan Chaligne
    Institut National de la Sante et de la Recherche Medicale INSERM, U790, Universite Paris XI, Institut Gustave Roussy, Villejuif, France
    Blood 110:3735-43. 2007
  9. ncbi [A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera]
    Valerie Ugo
    INSERM U 362, PR1, Institut Gustave Roussy, Villejuif, France
    Med Sci (Paris) 21:669-70. 2005
  10. doi Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia
    Dominique Bluteau
    INSERM, U1009, Villejuif, France
    Blood 118:6310-20. 2011

Collaborators

  • Valerie Ugo
  • William Vainchenker
  • Francois Xavier Mahon
  • Hana Raslova
  • Valerie Camara-Clayette
  • Gerard Socie
  • Marie Robin
  • Josef Prchal
  • Jean-Luc Villeval
  • Isabelle Godin
  • R Berger
  • Yann Lecluse
  • Francois Delhommeau
  • Sabrina Dupont
  • Jean Pierre Le Couedic
  • Olivier Mansier
  • Dominique Bluteau
  • Aline Massé
  • Nicole Casadevall
  • Frederic Larbret
  • Ronan Chaligne
  • Loic Garcon
  • Emmanuelle Verger
  • Audrey Bidet
  • Bruno Cassinat
  • Eric Lippert
  • Marina Migeon
  • Arnaud Saint-Lézer
  • Morgane Hilpert
  • Najet Debili
  • Veronique Cordette-Lagarde
  • Thomas Robert
  • Remi Favier
  • Sabina Swierczek
  • Patrick Gonin
  • Hugues Ripoche
  • Laure Gilles
  • Iléana Antony-Debré
  • Orianne Wagner-Ballon
  • Philippe Dessen
  • Fabienne Robert
  • Antonio Alberdi
  • Catherine Lacombe
  • Christophe Marzac
  • Veronique Della Valle
  • Michaela Fontenay
  • François J Dreyfus
  • Serge P Romana
  • Olivier A Bernard
  • Jean Soulier
  • Franck Viguie
  • Olivier Kosmider
  • Severine Trannoy
  • Isabelle Plo
  • Carole Tonetti
  • Frederic Mazurier
  • Fanny Fava
  • Serge Koscielny
  • Stephane Giraudier
  • Rodolphe Besancenot
  • Patrick Saulnier
  • Irene Teyssandier
  • Karim Maloum
  • Christine Rivat
  • Catherine Lacout
  • Annelise Bennaceur-Griscelli

Detail Information

Publications12

  1. ncbi A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
    Chloe James
    INSERM U362, Institut Gustave Roussy, Paris XI University, PR1, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Nature 434:1144-8. 2005
    ..As this mutation is also found in other myeloproliferative disorders, this unique mutation will permit a new molecular classification of these disorders and novel therapeutical approaches...
  2. doi The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?
    Chloe James
    Inserm U876, Universite Bordeaux 2, Bordeaux, France
    Hematology Am Soc Hematol Educ Program . 2008
    ..Recent investigations have also led to new treatment modalities that could benefit patients with PV...
  3. ncbi A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects
    Chloe James
    INSERM U362, Institut Gustave Roussy, Paris XI University, PR1, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Trends Mol Med 11:546-54. 2005
    ..Such a recurrent and unique mutation leading to a tyrosine kinase deregulation would make a suitable target for the development of specific therapies...
  4. doi The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity
    Chloe James
    INSERM, U876, Bordeaux, France
    Blood 112:2429-38. 2008
    ..These experiments provide new insights into the pathogenesis of JAK2V617F MPD and demonstrate that a JAK2 inhibitor needs to target the HSC compartment for optimal disease control in classical MPD...
  5. doi Mutation in TET2 in myeloid cancers
    Francois Delhommeau
    INSERM U790, Institut Gustave Roussy, Villejuif, France
    N Engl J Med 360:2289-301. 2009
    ..The myelodysplastic syndromes and myeloproliferative disorders are associated with deregulated production of myeloid cells. The mechanisms underlying these disorders are not well defined...
  6. ncbi The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera
    Sabrina Dupont
    INSERM Unité 790, Universite Paris Sud, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Blood 110:1013-21. 2007
    ....
  7. ncbi Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells
    Loic Garcon
    Unité U 790 Institut National de la Santé et de la Recherche Médicale INSERM, Institut Gustave Roussy, Villejuif, France
    Blood 108:1551-4. 2006
    ....
  8. ncbi Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis
    Ronan Chaligne
    Institut National de la Sante et de la Recherche Medicale INSERM, U790, Universite Paris XI, Institut Gustave Roussy, Villejuif, France
    Blood 110:3735-43. 2007
    ..In contrast, erythroid progenitors remained EPO dependent. These results demonstrate that in PMF, the MPL W515L or K mutation induces a spontaneous megakaryocyte (MK) differentiation and occurs in a multipotent HSCs...
  9. ncbi [A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera]
    Valerie Ugo
    INSERM U 362, PR1, Institut Gustave Roussy, Villejuif, France
    Med Sci (Paris) 21:669-70. 2005
  10. doi Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia
    Dominique Bluteau
    INSERM, U1009, Villejuif, France
    Blood 118:6310-20. 2011
    ..We propose that the down-regulation of NR4A3 in RUNX1-mutated hematopoietic progenitors leads to an increase in the pool of cells susceptible to be hit by secondary leukemic genetic events...
  11. ncbi New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients
    Jean Luc Villeval
    INSERM, U790, Institut Gustave Roussy, IGR, Villejuif, France
    Semin Thromb Hemost 32:341-51. 2006
    ....
  12. doi Quantification of the Mutant CALR Allelic Burden by Digital PCR: Application to Minimal Residual Disease Evaluation after Bone Marrow Transplantation
    Olivier Mansier
    Hematology Laboratory, CHU de Bordeaux, Bordeaux, France Leukemic Hematopoiesis and Therapeutic Targets Laboratory, Biothérapie des maladies génétiques et cancers, Universite de Bordeaux, Bordeaux, France
    J Mol Diagn 18:68-74. 2016
    ..In conclusion, digital PCR adapted to type 1 and 2 CALR mutations is an inexpensive, highly precise, and sensitive technique suitable for evaluation of myeloproliferative neoplasm patients during follow-up. ..